Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, ...
Seeking Alpha

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on ...
Business Insider

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale ...

THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a ...
Nasdaq

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its commercial ...
Seeking Alpha

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX) today announced that Lonnel Coats has provided notice of his retirement as chief executive ...
Nasdaq

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company has submitted additional clinical data to the U.S. Food and Drug ...